Reni J. Analyst PerformanceAnalyst at Citizens JmpReni J. is a stock analyst at Citizens Jmp focused in the medical sector, covering 15 publicly traded companies. Over the past year, Reni J. has issued 21 stock ratings, including buy and hold recommendations. While full access to Reni J.'s proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Reni J.'s coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings21 Last 0 YearsBuy Recommendations95.24% 20 Buy RatingsCompanies Covered15 Unique Companies Ratings Distribution21RatingsDistribution of strong buy, buy, hold, and sell ratings by Reni J..RatingPercentageCount Strong Buy0.0%0 ratings Buy95.2%20 ratings Hold4.8%1 ratings Sell0.0%0 ratingsOut of 21 total stock ratings issued by Reni J. at Citizens Jmp, the majority (95.2%) have been Buy recommendations, followed by 4.8% Hold.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ15 companiesReni J., an analyst at Citizens Jmp, currently covers 15 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical14 companies93.3%Manufacturing1 company6.7%Reni J. of Citizens Jmp specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE10 companies66.7%MED - DRUGS4 companies26.7%PHARMACEUTICAL PREPARATIONS1 company6.7% Reni J.'s Ratings History at Citizens Jmp Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCMPXCompass Therapeutics4/28/2026Reiterated Rating$1.97$10.00Market Outperform$0.0000.00% ROISTROSutro Biopharma4/23/2026Boost Price Target$35.32$41.00Market Outperform$0.0000.00% ROISTROSutro Biopharma4/17/2026Boost Price Target$30.28$35.00Market Outperform$0.0000.00% ROIWHWKWhitehawk Therapeutics4/16/2026Initiated Coverage$3.90$8.00Market Outperform$0.0000.00% ROIALLOAllogene Therapeutics4/14/2026Boost Price Target$3.04$8.00Market Outperform$0.0000.00% ROIBCAXBicara Therapeutics3/31/2026Reiterated Rating$19.04$31.00Market Outperform$0.0000.00% ROIIMMXImmix Biopharma3/27/2026Reiterated Rating$9.02$23.00Market Outperform$0.0000.00% ROIIMMPPrima BioMed3/13/2026Downgrade$2.76Market Perform$0.0000.00% ROILYELLyell Immunopharma3/9/2026Initiated Coverage$22.46$34.00Market Outperform$0.0000.00% ROIIOVAIovance Biotherapeutics3/3/2026Upgrade$3.79$5.00Market Outperform$0.0000.00% ROIIMMPPrima BioMed2/23/2026Initiated Coverage$2.79$10.00Market Outperform$0.0000.00% ROISMMTSummit Therapeutics1/30/2026Reiterated Rating$15.40$40.00Market Outperform$0.0000.00% ROIONCBeOne Medicines11/7/2025Boost Price Target$332.36$396.00Market Outperform$0.0000.00% ROISANASana Biotechnology10/30/2025Boost Price Target$5.37$8.00Market Outperform$0.0000.00% ROISMMTSummit Therapeutics10/20/2025Reiterated Rating$20.31$40.00Market Outperform$0.0000.00% ROIKURAKura Oncology10/20/2025Reiterated Rating$9.82$24.00Market Outperform$0.0000.00% ROISMMTSummit Therapeutics9/3/2025Reiterated Rating$24.15$40.00Market Outperform$0.0000.00% ROISMMTSummit Therapeutics8/19/2025Reiterated Rating$26.29$40.00Market Outperform$0.0000.00% ROIPRLDPrelude Therapeutics8/18/2025Lower Price Target$0.87$3.00Market Outperform$0.0000.00% ROIBCYCBicycle Therapeutics8/12/2025Lower Price Target$7.46$10.00Market Outperform$0.0000.00% ROIKURAKura Oncology8/11/2025Lower Price Target$5.54$24.00Market Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenMorgan StanleyRoyal Bank Of CanadaBerenberg BankUBS GroupCitigroupBarclaysWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
